Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024897
Filing Date
2022-11-14
Accepted
2022-11-14 14:19:23
Documents
115
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q gls-20220930.htm   iXBRL 10-Q 4971528
2 EX-10.4 gls-ex10_4.htm EX-10.4 87780
3 EX-31.1 gls-ex31_1.htm EX-31.1 19927
4 EX-31.2 gls-ex31_2.htm EX-31.2 23224
5 EX-32.1 gls-ex32_1.htm EX-32.1 14369
6 EX-32.2 gls-ex32_2.htm EX-32.2 14362
7 GRAPHIC img65377977_0.jpg GRAPHIC 27363
  Complete submission text file 0000950170-22-024897.txt   17139574

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT gls-20220930_cal.xml EX-101.CAL 81644
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT gls-20220930_def.xml EX-101.DEF 463144
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gls-20220930.xsd EX-101.SCH 119657
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gls-20220930_pre.xml EX-101.PRE 647788
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gls-20220930_lab.xml EX-101.LAB 782677
109 EXTRACTED XBRL INSTANCE DOCUMENT gls-20220930_htm.xml XML 3240697
Mailing Address 501 BOYLSTON STREET, SUITE 6102 BOSTON MA 02116
Business Address 501 BOYLSTON STREET, SUITE 6102 BOSTON MA 02116 857-327-7737
GELESIS HOLDINGS, INC. (Filer) CIK: 0001805087 (see all company filings)

EIN.: 844730610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39362 | Film No.: 221383745
SIC: 2834 Pharmaceutical Preparations